Search Results
Site Search
State-of-the-art genetics panel optimizes kidney disease treatment - Insights
Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive, accurate and actionable results. Identifying a genetic cause helps guide the complex decisions...
Test helps identify elusive central nervous system pathogens: Robin Patel, M.D. - Insights
Robin Patel, M.D., explains how a new Mayo Clinic Laboratories' assay can identify central nervous system pathogens that standard tests fail to detect. Rapid, precise diagnosis is essential to preventing long-term effects from these...
Mayo Clinic Labs @Work: Shannon Bennett - Insights
As director of Regulatory Affairs for the Department of Laboratory Medicine and Pathology, Shannon Bennett helps safeguard Mayo Clinic’s reputation for quality care by ensuring that its clinical laboratories operate at the highest level of...
Mayo Clinic Labs @Work: Lisa Wortman Raring - Insights
In her role as a proposal writer, Lisa Wortman Raring helps show clients everything Mayo Clinic Laboratories has to offer, making it clear how the organization can best meet their needs and the needs of their patients.
Seeking, and finding, answers, comfort, and hope: Joe Mondloch - Insights
Joe Mondloch and his wife Sue have existed in a grey area of uncertainty due to the unpredictable autoimmune neurological illness Joe has lived with for the last seven years. Rare, incurable, and debilitating, the newly classified disorder...
What's New in Health Care Reform: Dec. 26 - Insights
Top highlights include: FDA panel backs prescribing opioid overdose reversal drug along with painkillers, Surgeon General warns youth vaping is now an "epidemic," international patients seeking cures in the states, Mayo Clinic President and...
Dangerous Goods Training - Insights
Self-paced online training and certification for safe collection, handling, packaging, and shipment of specimens.
MASTERMIND: A Smarter Search for Microbial Diagnostics - Insights
In the war against microbes, human beings are vastly outnumbered—and losing the weapons race.
In a recent issue of Mayo Clinic's Digestive Diseases, Michael Camilleri, M.D., a gastroenterologist at Mayo Clinic, and Leslie Donato, Ph.D., Co-Director for Cardiovascular Laboratory Medicine, Hospital Clinical Laboratory, and Point of...
Research Suggests Genetics Are Key in Treating Night Sweats - Insights
Hormone therapy is often used to prevent night sweats. But finding the right dose of estrogen can be tricky, with some women needing more estrogen than others to get relief. A new Mayo Clinic study published in Menopause: The Journal of the...
Mayo Clinic Laboratory and pathology research roundup: September 26 - Insights
This week's research roundup feature: Semaglutide in HFpEF across obesity class and by body weight reduction.
Hereditary Oncology Testing [Test in Focus] - Insights
Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant...
Cholesterol biosynthesis and transport - Insights
Check out Mayo Clinic Laboratories’ testing approach to diagnose disorders related to cholesterol biosynthesis and transport.
Peroxisomal biogenesis and metabolism - Insights
Learn more about how Mayo Clinic Laboratories’ testing for peroxisomal biogenesis and metabolism disorders can assist in the identification of these sometimes fatal conditions.
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in...
Mayo Clinic Laboratories upfront, screening enzyme-linked immunosorbent assay detects Coccidioides antibodies prior to testing by complement fixation (CF) or immunodiffusion (ID). Samples that result as reactive by are subsequently reflexed...
Biopharma solutions - Insights
Inspired by Mayo Clinic’s tradition of collaboration to break down barriers, expand knowledge, and change medicine, BioPharma Diagnostics brings unmatched expertise and quality to each project. Whether supporting clinical trials, advancing...
Hereditary neuromuscular disorders - Insights
Find out how our distinctive approach to evaluating for inherited neuromuscular disorders uses phenotypic information to streamline diagnosis.
Primary ciliary dyskinesia - Insights
Learn more about Mayo Clinic Laboratories’ robust approach to testing for primary ciliary dyskinesia, a rare genetic condition that can lead to chronic otosinopulmonary disease and infertility in men.
Amino acid disorders - Insights
Learn more about how amino acid metabolism testing at Mayo Clinic Laboratories can assist in diagnosing the most preventable and treatable amino acid disorders.
Browse our menu of immunoglobulin E (IgE) antibody testing, which can be useful in the evaluation of patients suspected of having an allergic disease.
Colorectal Cancer NGS Testing - Mayo Clinic Laboratories
Our panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.
Week in Review: April 8 - Insights
Today's Highlights Include: 5 reasons to consider becoming an organ donor, why so many women in middle age are on antidepressants, and should you get a second COVID-19 vaccine booster?
Mayo Clinic Laboratory and Pathology Research Roundup: December 26 - Insights
This week's research roundup feature: Histoplasma and Blastomyces antigen detection assays are commonly used diagnostic tools. However, a high level of cross-reactivity between these antigens prevents definitive pathogen identification by...
Assay enhances and simplifies M-proteins screening: David Murray, M.D., Ph.D. - Insights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASSFIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the...
Thrombotic Microangiopathies (TMA) [Test in Focus] - Insights
Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to...
Mayo Clinic Laboratory and Pathology Research Roundup: March 12 - Insights
This week's research roundup feature: C3 glomerulopathy (C3G) is a rare disease resulting from dysregulation of the alternative pathway of complement. C3G includes C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), both of which...
Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D. - Insights
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating...
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon,...
Neurofascin 155 IgG4 Antibody Test [Test in Focus] - Insights
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of...
Five steps for successful outreach program implementation - Insights
Learn the five elements essential to successfully implementing a complex outreach program project and what is at risk if you miss an element.
Learn more about educational offerings available to primary clients of Mayo Clinic Laboratories.
New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...
Mayo Clinic Laboratories and Progentec launch lupus advanced biomarker testing services - Insights
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing...
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels,...
Urologic panels provide focused cancer testing: Sounak Gupta, M.B.B.S., Ph.D. - Insights
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS...
Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. - Insights
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal...
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test...
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted...
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. - Insights
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely...
Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for...
Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related...
Disaccharidase Activity Panel [Test in Focus] - Insights
Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac...
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild...
Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk...
Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for...
Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D. - Insights
John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of...